Home Online Features Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Press Releases
Palatin Technologies, Inc.  
March 31, 2025

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Primary endpoint met in the 8-week treatment study (highly statistically significant).Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001).Primary analysis for the co-administered

Salamanca Press

Local & Social
Latest news for you
Dunkirk upends Salamanca’s unbeaten start
Local Sports, Salamanca Sports, Sports, ...
Dunkirk upends Salamanca’s unbeaten start
JP BUTLER Salamanca Press 
April 26, 2025
SALAMANCA — Through an unbeaten 7-0 start, the Salamanca baseball team had established a clear identity. The Warriors played cleanly. They ran the bas...
Read More...
Cattaraugus County Source
ePaper
google_play
app_store
This Week's Ads
Current e-Edition
ePaper
google_play
app_store
Already a subscriber? Click the image to view the latest e-edition.
Don't have a subscription? Click here to see our subscription options.
Mobile App

Download Now

The Salamanca Press mobile app brings you the latest local breaking news, updates, and more. Read the Salamanca Press on your mobile device just as it appears in print.

ePaper
google_play
app_store
Trending Recipes

Help Our Community

Please help local businesses by taking an online survey to help us navigate through these unprecedented times. None of the responses will be shared or used for any other purpose except to better serve our community. The survey is at: www.pulsepoll.com $1,000 is being awarded. Everyone completing the survey will be able to enter a contest to Win as our way of saying, "Thank You" for your time. Thank You!